Lisaftoclax (APG-2575): In CLL/SLL Treatment: Safety and Efficacy as Monotherapy or Combined with Acalabrutinib or Rituximab Matthew Davids MD - Synopsis below extracted from the video transcript.
Acalabrutinib (AVO): A Promising New Triplet Treatment Option for High-Risk CLL Patients Phase 2 Study Results Matthew Davids MD - Synopsis below extracted from the video transcript.
Zanubrutinib Outperforms Ibrutinib in Treating Relapsed/Refractory CLL/SLL Dr. Mobasher - Synopsis below extracted from the video transcript.